DSUVIA

October was a volatile month for the markets, and biotech stocks were no exception. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) had slipped about 17 percent in the period. This compares to S&P 500's 7 percent retreat. As we enter the last leg of the year, here are a few PDUFA...

A day after Trevena Inc (NASDAQ: TRVN) shares suffered a setback in reaction to a FDA committe's briefing document, another stock is trading higher following the release of a briefing document pertaining to its adcom review. What Happened The briefing document released by FDA's...

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) shares have been on a tear and are trading near a two-year high after speculation started doing the rounds that its pain treatment candidate DSUVIA is poised to get early approval. About 3.25 million shares exchanged hands, roughly 2.5 times the average...

It isn't easy being a small pharmaceutical company banking on FDA approval of a painkiller product in a nation gripped by an opioid epidemic. Consider AcelRx Pharmaceuticals Inc (NASDAQ: ACRX), which has developed a fast, under-the-tongue delivery system for the opioid called sufentanil. It...